MedTrace Logo

Benzydamine vs Supersaturated Calcium Phosphate Oral Rinses for Radiation Induced Oral Mucositis in Head and Neck Cancer Patients.

NCT07748442 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-08-05

No results posted yet for this study

Summary

The goal of this clinical trial is to compare and correlate salivary macrophage migratory inhibitory factor levels with onset and severity of radiation induced mucositis in head and neck cancer patients by using super saturated calcium phosphate solution and benzydamine hydrochloride oral rinses. Participants are patients of head and neck cancers undergoing radiation therapy of either gender.

participants are divided into two groups Group A: Benzydamine group Group B: Super saturated calcium phosphate group

* Participants will be using Oral rinses of their respective group and will be assessed for radiation induced oral mucositis at weekly intervals during radiation treatment.
* salivary Macrophage migratory inhibitory factor levels will be assessed through ELISA, before and after the radiation treatment as per protocol.

Conditions

  • Radiation Induced Oral Mucositis

Interventions

DRUG

Benzydamine hydrochloride mouthrinse

Comparison of Salivary macrophage migratory inhibitory factor through ELISA in both the intervention groups and observing onset and severity of oral mucositis in both groups

DRUG

Super saturated calcium phosphate oral rinses

salivary Macrophage migratory inhibitory factors will be assessed before and after radiation therapy

Sponsors & Collaborators

  • Postgraduate Medical Institute, Lahore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-13
Primary Completion
2023-03-31
Completion
2023-04-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748442 on ClinicalTrials.gov